Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AVITA Medical (RCEL) EBITDA (2018 - 2025)

AVITA Medical (RCEL) has disclosed EBITDA for 7 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 34.86% year-over-year to $21.9 million, compared with a TTM value of -$10.2 million through Dec 2025, up 21.39%, and an annual FY2025 reading of -$10.2 million, up 21.39% over the prior year.
  • EBITDA was $21.9 million for Q4 2025 at AVITA Medical, up from -$9.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $33.7 million in Q4 2024 and bottomed at -$17.2 million in Q1 2024.
  • Average EBITDA over 4 years is -$2.3 million, with a median of -$9.4 million recorded in 2022.
  • The sharpest move saw EBITDA crashed 75.5% in 2023, then soared 46.56% in 2024.
  • Year by year, EBITDA stood at $16.0 million in 2022, then surged by 43.49% to $23.0 million in 2023, then soared by 46.56% to $33.7 million in 2024, then plummeted by 34.86% to $21.9 million in 2025.
  • Business Quant data shows EBITDA for RCEL at $21.9 million in Q4 2025, -$9.2 million in Q3 2025, and -$11.1 million in Q2 2025.